Market Place
Sourcing Support
Ingenus Pharm`s Generic Lifitegrast Receives Tentative Approval in US
04 Jun 2024 //
FDA
AuraMedics` Generic Lifitegrast Receives Approval in the U.S.
07 Nov 2023 //
FDA
Bausch + Lomb Announces Expiration of Hart-Scott-Rodino Waiting Period for Acquisition of XIIDRA
24 Aug 2023 //
BUSINESSWIRE
Micro Labs` Generic Lifitegrast Receives Approval in the U.S.
04 Aug 2023 //
FDA
Bausch + Lomb buys Novartis drugs for $1.75 billion to boost eye-care portfolio
01 Jul 2023 //
REUTERS
Novartis targets Xiidra in eye disease asset sale
14 Mar 2023 //
FIERCE PHARMA
Ingenus` Generic Lifitegrast Receives Approval in the U.S.
15 Feb 2023 //
FDA
Sun`s Generic Lifitegrast Receives Approval in the U.S.
11 Jan 2023 //
FDA
Enforcement Report - Week of June 15, 2022
14 Jun 2022 //
FDA
Japan`s Takeda expects $200M operating loss to Novartis` Xiidra withdrawal
29 Jun 2020 //
REUTERS
Novartis pulls Takeda-bought dry eye med Xiidra in Europe
27 Jun 2020 //
FIERCE PHARMA
Zogenix`s Fintepla ready to challenge GW Pharma in rare epilepsy
26 Jun 2020 //
FIERCEPHARMA
Takeda recalls eye drug Natpara, warns patients not to abruptly stop treatment
07 Sep 2019 //
FIERCEPHARMA
FDA rejects Kala`s dry eye drug; Troubled Insys finds a buyer in Hikma
10 Aug 2019 //
ENDPTS
Still on a cash-raising spree, Takeda shops €1.5B European drug sale: report
19 Jul 2019 //
FIERCE PHARMA
Novartis offloads lagging endocrine drugs to Recordati for $390M
16 Jul 2019 //
FIERCE PHARMA
Takeda investors want executives to return pay if performance lags
03 Jul 2019 //
FIERCE PHARMA
Aldeyra`s eye drug fails pivotal test for rare, inflammatory disease
25 Jun 2019 //
ENDPTS
Novartis to acquire Xiidra in a $5.3B deal
10 May 2019 //
BIOSPECTRUMASIA
Novartis buys Takeda`s dry eye drug for $3.4 bln
09 May 2019 //
CNBC
A Dry Eye treatment aimed at mitochondria
15 Apr 2019 //
FIERCE BIOTECH
Takeda eyes $3B from emerging-market asset cull
22 Jan 2019 //
FIERCE PHARMA
Takeda`s $80 Billion Acquisition of Shire Hits Snag in Europe
29 Oct 2018 //
BIOSPACE
Aldeyra has positive dry eye data — for now
27 Sep 2018 //
BIOPHARMA DIVE
Takeda Is Said to Weigh Sale of Shire Eye Drug to Cut Debt
14 Sep 2018 //
BLOOMBERG
Takeda weighs sale of Shire`s eye care business to cut debt- Bloomberg
13 Sep 2018 //
CNBC
Oyster Point posts positive Phase IIb data for rival drug
13 Jul 2018 //
ENDPTS
Wize Pharma appoints Joseph Tauber on Scientific Advisory Board
16 Mar 2018 //
BIOSPECTRUM
Shire seeks European approval for dry-eye disease drops
16 Aug 2017 //
TELEGRAPH
Shire licences Parion dry eye drug in $535m deal
03 May 2017 //
PMLIVE
Allergan’s multidose Restasis nabs FDA approval & battle with Shire’s Xiidra
20 Apr 2017 //
FIERCE PHARMA
Novartis takes home rights to Lubris’ eye drug
08 Apr 2017 //
PHARMA TIMES
Allergan urges dry-eye sufferers to pump up their eye power
13 Mar 2017 //
FIERCE PHARMA
Allergan takes on preventable blindness with nationwide vision-screening push
09 Feb 2017 //
FIERCE PHARMA
Mylan Scores Review of Allergan`s Restasis IP
10 Dec 2016 //
FIERCE PHARMA
Fitch Affirms Allergan at `BBB-`; Outlook Stable
08 Dec 2016 //
REUTERS
Sun buys Ocular, late-stage dry-eye candidate to take on Allergan blockbuster
02 Nov 2016 //
FIERCE PHARMA
